Related Experiment Video
Updated: Jan 4, 2026
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
Published on: December 1, 2013
New agents for bladder cancer
1University Hospital del Mar, Barcelona, Spain. jbellmunt@imas.imim.es
Abstract:
Muscle-invasive bladder cancer is an aggressive disease with at least 50% of patients dying from metastases within 2 years of diagnosis. The 5-year survival rate for metastatic bladder cancer is <15%. Although modern combination chemotherapy regimens have improved median survival from 6 to 14 months compared with best supportive care, there is still a great opportunity for improvement. New therapies and strategies for better patient and treatment selection are now being investigated for advanced bladder cancer. These include agents that target several pathways involved in the pathogenesis of the disease--such as growth factor receptors, angiogenic pathways, p53, cell cycle checkpoints and apoptosis--as well as novel chemotherapeutic agents. Results from recent and ongoing trials suggest that some of these agents could soon emerge as useful players to overcome the limitations of our present therapies.
Insights
Muscle-invasive bladder cancer is aggressive, with poor survival rates. New targeted therapies and improved patient selection strategies show promise for overcoming current treatment limitations in advanced bladder cancer.
Area of Science:
- Oncology
- Cancer Research
Background:
- Muscle-invasive bladder cancer (MIBC) is an aggressive malignancy with high metastatic potential.
- Current 5-year survival rates for metastatic bladder cancer are below 15%, indicating a significant unmet need.
- While chemotherapy has improved survival, further advancements are crucial for better patient outcomes.
Purpose of the Study:
- To review emerging therapies and strategies for advanced bladder cancer.
- To highlight novel agents targeting key oncogenic pathways.
- To discuss the potential of improved patient and treatment selection.
Main Methods:
- Review of recent and ongoing clinical trials in advanced bladder cancer.
- Analysis of novel therapeutic agents targeting growth factor receptors, angiogenesis, p53, cell cycle, and apoptosis.
- Examination of strategies for patient and treatment selection.
Main Results:
- New therapeutic agents targeting critical cancer pathways are under investigation.
- Ongoing trials are evaluating novel chemotherapeutic agents and targeted therapies.
- Emerging data suggests these novel approaches may offer improved efficacy.
Conclusions:
- Significant opportunities exist to improve outcomes for patients with advanced bladder cancer.
- Targeted therapies and novel agents show promise in overcoming current treatment limitations.
- Future research focuses on personalized medicine approaches for bladder cancer treatment.
More Related Videos
11:02Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
08:43An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
Published on: July 28, 2012
Related Concept Videos
01:19Anatomy of the Genitourinary System II: Bladder and Urethra
01:30Urinary Tract Calculi III: Medical Management
01:23Urinary Bladder
In males, the bladder is situated in front of the rectum, while in females, it is positioned anterior to the vagina and uterus. The bladder floor contains an inverted triangular area called the trigone, defined by the two ureteric...
02:56Treatment Resistant Cancers